BioStock Investor Pitch: ExpreS2ion Biotechnologies

Danish ExpreS2ion Biotechnologies develops a portfolio of vaccines currently targeting Covid-19, breast cancer, influenza, malaria and, with the latest pipeline addition, the cytomegalovirus. The company is currently looking to raise 102 MSEK in a rights issue to finance the next step with the ES2B-C001 breast cancer vaccine. CEO Bent U. Frandsen tells us more about the ongoing activities in  BioStock Investor Pitch today at 08.45 am. 

See the presentation at biostock.se:

https://www.biostock.se/2023/04/biostock-investor-pitch-expres2ion-biotechnologies-2/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se